Citius Pharmaceuticals (NASDAQ:CTXR) Announces Quarterly Earnings Results, Misses Estimates By $1.34 EPS

Citius Pharmaceuticals (NASDAQ:CTXR) posted its quarterly earnings data on Friday. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of $0.39 by ($1.34), FiscalAI reports.

Citius Pharmaceuticals Stock Down 2.7%

CTXR stock traded down $0.02 during trading on Friday, hitting $0.70. The company had a trading volume of 516,793 shares, compared to its average volume of 1,069,212. The firm has a 50-day moving average price of $0.79 and a 200-day moving average price of $0.92. Citius Pharmaceuticals has a 12 month low of $0.57 and a 12 month high of $2.48. The stock has a market cap of $15.67 million, a price-to-earnings ratio of -0.29 and a beta of 1.05.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. D. Boral Capital restated a “buy” rating and issued a $6.00 price objective on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $6.00.

Institutional Trading of Citius Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Heights Capital Management Inc. bought a new stake in shares of Citius Pharmaceuticals during the 4th quarter valued at $622,000. XTX Topco Ltd raised its position in shares of Citius Pharmaceuticals by 572.8% during the 4th quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock valued at $83,000 after acquiring an additional 91,196 shares during the last quarter. Asset Advisory Group Inc. bought a new stake in shares of Citius Pharmaceuticals during the 4th quarter valued at $46,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Citius Pharmaceuticals during the 2nd quarter valued at $40,000. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.